{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:17:34Z","timestamp":1794651454690,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.eururo.2011.10.029","type":"journal-article","created":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T07:12:58Z","timestamp":1319613178000},"page":"118-125","source":"Crossref","is-referenced-by-count":233,"title":["Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1016","volume":"62","author":[{"given":"Joan","family":"Palou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Rodr\u00edguez","family":"Faba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Parada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Algaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Villavicencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.10.029_bib0005","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0010","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","article-title":"Primary superficial bladder cancer risk groups according to progression, mortality and recurrence","volume":"164","author":"Mill\u00e1n-Rodr\u00edguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0015","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Club Urol\u00f3gico Espa\u00f1ol De Tratamiento Oncol\u00f3gico (CUETO). Prognostic factors in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fern\u00e1ndez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","article-title":"Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients","volume":"48","author":"Orsola","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0025","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0030","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2010.09572.x","article-title":"Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Gru\u00e8rin treatment","volume":"107","author":"Kakiashvili","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.10.029_bib0040","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1442-2042.2007.01890.x","article-title":"Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients","volume":"14","author":"Denzinger","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0045","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0050","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-G\u00f3mez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0060","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2003.09.013","article-title":"Bladder carcinoma in situ in 2003: state of the art","volume":"45","author":"Witjes","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0065","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.eururo.2009.07.005","article-title":"Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer","volume":"56","author":"Dalbagni","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0070","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0090-4295(99)80481-6","article-title":"In situ transitional cell carcinoma involvement of prostatic urethra: bacille Calmette-Guerin therapy without previous transurethral resection of the prostate","volume":"47","author":"Palou","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.10.029_bib0075","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2005.12.019","article-title":"Intravesical instillations with bacillus Calmette-Gu\u00e9rin for the treatment of carcinoma in situ involving prostatic ducts","volume":"49","author":"Palou","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0080","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0022-5347(01)66762-4","article-title":"The prostate involvement as prognostic factor in patients with superficial bladder tumors","volume":"154","author":"Solsona","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0085","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-5347(01)66338-9","article-title":"Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications","volume":"155","author":"Solsona","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0090","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0090-4295(00)00523-9","article-title":"Gender differences in stage-adjusted bladder cancer survival","volume":"55","author":"Mungan","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.10.029_bib0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0090-4295(95)96490-8","article-title":"Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer","volume":"45","author":"Angulo","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.10.029_bib0100","series-title":"WHO classification of tumours: pathology and genetics of the urinary system and male genital organs","first-page":"107","article-title":"Infiltrating urothelial carcinoma","author":"L\u00f3pez-Beltr\u00e1n","year":"2004"},{"key":"10.1016\/j.eururo.2011.10.029_bib0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1442-2042.1997.tb00160.x","article-title":"Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Gu\u00e9rin: a long-term follow-up","volume":"4","author":"Shinka","year":"1997","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0115","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","article-title":"Bacillus Calmette-Gu\u00e9rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder: four-year results. The Bladder Cancer BCG Study Group","volume":"75","author":"Akaza","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.10.029_bib0120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0125","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1464-410X.2008.07966.x","article-title":"Quality control in transurethral resection of bladder tumours","volume":"102","author":"Herr","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.10.029_bib0130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0302-2838(03)00040-X","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumours","volume":"43","author":"Miladi","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.029_bib0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2008.09.062","article-title":"Protein expression patterns of erzin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin","volume":"56","author":"Palou","year":"2009","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811011353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811011353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:57:22Z","timestamp":1543453042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811011353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0302283811011353"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.10.029","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}